Erleva 100 mg Tablet
  1. Home
  2. Pharma Products
  3. Glenmark Pharmaceuticals Ltd
  4. Erleva 100 mg Tablet

Erleva 100 mg Tablet

Erleva 100 mg Tablet contains erlotinib 100 mg and is an oral targeted anticancer medicine used mainly in the treatment of non-small cell lung cancer and pancreatic cancer. It is taken by mouth on an empty stomach according to the prescribed treatment plan. Erlotinib blocks EGFR signaling, which can help slow the growth of certain cancer cells.

BUY NOW

Category

Erleva belongs to the tyrosine kinase inhibitor class and is used in appropriate treatment regimens for specific types of advanced or metastatic non-small cell lung cancer and pancreatic cancer. By inhibiting EGFR signaling, erlotinib interferes with cellular pathways involved in the growth and multiplication of susceptible cancer cells. The 100 mg strength is taken orally according to the oncologist’s prescribed schedule, with treatment duration determined by disease response and clinical assessment. Patients may require monitoring for skin reactions, diarrhea, liver abnormalities, and other treatment-related effects.

Technical Specification

Specification Details
Active Ingredient Erlotinib
Strength 100 mg
Dosage Form Tablet
Route of Administration Oral
Therapeutic Class Antineoplastic
Marketer Glenmark Pharmaceuticals Ltd

Product Also Known As

Erleva 100mg Tablet, Erleva 100 mg Tablet, Erlotinib 100mg Tablet, Erlotinib 100 mg Tablet, Erlotinib Tablets 100mg, Erlotinib EGFR Inhibitor Tablet